Chugai Pharmaceutical (CHGCY.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Nov26

Chugai Pharmaceutical's Subsidiary Reports Positive Phase 3 Clinical Trial Results for Sparsentan in Japan

06:31

Nov25

中外制药 collaborates with Biomy to develop cancer pathology diagnosis support program

11:02

Nov18

Otsuka Pharmaceutical to fully acquire and merge Renalys Pharma

11:03

Oct26

Otsuka Pharmaceutical Acquires Renalys Pharma and Multiple Biotech Stocks Fluctuate

18:02

Oct25

Chugai Pharmaceutical released FY2025 Q3 earnings on October 24 (EST), actual revenue USD 2.242 B (forecast USD 2.244 B), actual EPS USD 0.2273

03:00

Chugai Pharmaceutical released FY2025 9 Months earnings on October 24 (EST), actual revenue USD 6.171 B, actual EPS USD 0.6285

03:00

Schedules & Filings

Schedules

Filings

Jan29

Earning Release(EST)

FY2025 Annual Earning Release

Oct24

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 2.242 B, Net Income 748.25 M, EPS 0.2273

Jul24

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 2.003 B, Net Income 671.15 M, EPS 0.2039

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More